Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles.
DAMP
NANPs
PAMP
PRR
immunomodulation
innate immune system
therapy
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
09
2022
accepted:
18
01
2023
entrez:
17
2
2023
pubmed:
18
2
2023
medline:
22
2
2023
Statut:
epublish
Résumé
The immune system has evolved to defend organisms against exogenous threats such as viruses, bacteria, fungi, and parasites by distinguishing between "self" and "non-self". In addition, it guards us against other diseases, such as cancer, by detecting and responding to transformed and senescent cells. However, for survival and propagation, the altered cells and invading pathogens often employ a wide range of mechanisms to avoid, inhibit, or manipulate the immunorecognition. As such, the development of new modes of therapeutic intervention to augment protective and prevent harmful immune responses is desirable. Nucleic acids are biopolymers essential for all forms of life and, therefore, delineating the complex defensive mechanisms developed against non-self nucleic acids can offer an exciting avenue for future biomedicine. Nucleic acid technologies have already established numerous approaches in therapy and biotechnology; recently, rationally designed nucleic acids nanoparticles (NANPs) with regulated physiochemical properties and biological activities has expanded our repertoire of therapeutic options. When compared to conventional therapeutic nucleic acids (TNAs), NANP technologies can be rendered more beneficial for synchronized delivery of multiple TNAs with defined stabilities, immunological profiles, and therapeutic functions. This review highlights several recent advances and possible future directions of TNA and NANP technologies that are under development for controlled immunomodulation.
Identifiants
pubmed: 36798121
doi: 10.3389/fimmu.2023.1053550
pmc: PMC9927404
doi:
Substances chimiques
Nucleic Acids
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1053550Subventions
Organisme : NIGMS NIH HHS
ID : R35 GM139587
Pays : United States
Informations de copyright
Copyright © 2023 Panigaj, Skelly, Beasock, Marriott, Johnson, Salotti and Afonin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Explor Target Antitumor Ther. 2021;2(1):107-121
pubmed: 36046085
Nanoscale. 2018 Sep 27;10(37):17761-17770
pubmed: 30215080
Nat Nanotechnol. 2021 Jun;16(6):630-643
pubmed: 34059811
Cell. 2018 Mar 8;172(6):1239-1259
pubmed: 29522745
Sci Signal. 2019 Oct 29;12(605):
pubmed: 31662487
Adv Immunol. 2001;78:1-56
pubmed: 11432202
Immunity. 2011 May 27;34(5):680-92
pubmed: 21616437
Chem Biol. 2008 Jul 21;15(7):675-82
pubmed: 18635004
Oncotarget. 2016 May 3;7(18):26496-515
pubmed: 27034163
Nucleic Acids Res. 2020 Nov 18;48(20):11785-11798
pubmed: 33091133
Nat Rev Immunol. 2008 Jul;8(7):559-68
pubmed: 18575461
J Leukoc Biol. 2016 Jul;100(1):27-45
pubmed: 27162325
Molecules. 2018 Dec 02;23(12):
pubmed: 30513826
Immunity. 2020 Jul 14;53(1):78-97
pubmed: 32668230
ACS Nano. 2021 Nov 23;15(11):16957-16973
pubmed: 34677049
Small. 2017 Nov;13(42):
pubmed: 28922553
Nucleic Acids Res. 2021 Dec 2;49(21):12017-12034
pubmed: 34850129
Molecules. 2021 Jan 27;26(3):
pubmed: 33513786
Curr Opin Biotechnol. 2020 Jun;63:8-15
pubmed: 31778882
ACS Nano. 2020 Aug 25;14(8):9221-9227
pubmed: 32706238
Cancer Immunol Res. 2014 Sep;2(9):867-77
pubmed: 24938283
Nature. 2015 Oct 1;526(7571):55-61
pubmed: 26432244
Small. 2022 Apr;18(13):e2104814
pubmed: 35128787
Cell. 2018 May 3;173(4):906-919.e13
pubmed: 29706547
Nanomaterials (Basel). 2019 Apr 12;9(4):
pubmed: 31013847
ACS Appl Mater Interfaces. 2020 Sep 2;12(35):38873-38886
pubmed: 32805923
Nanomedicine. 2020 Nov;30:102285
pubmed: 32781137
Nano Lett. 2014 Oct 8;14(10):5662-71
pubmed: 25267559
Cancer Immunol Res. 2017 Nov;5(11):950-956
pubmed: 28963140
Nano Lett. 2016 Mar 9;16(3):1746-53
pubmed: 26926382
Mol Ther Nucleic Acids. 2020 Jun 5;20:359-372
pubmed: 32200271
Nat Rev Immunol. 2012 Jun 22;12(7):479-91
pubmed: 22728526
Nanoscale. 2016 Oct 14;8(40):17542-17550
pubmed: 27714127
Nucleic Acids Res. 2019 Feb 20;47(3):1350-1361
pubmed: 30517685
Virology. 1996 May 15;219(2):339-49
pubmed: 8638399
Nucleic Acids Res. 2012 Mar;40(6):2724-33
pubmed: 22127865
Molecules. 2021 Jul 12;26(14):
pubmed: 34299506
Recent Pat Anticancer Drug Discov. 2018;13(1):2-17
pubmed: 29086701
Sci Transl Med. 2018 May 2;10(439):
pubmed: 29720451
Annu Rev Microbiol. 2018 Sep 08;72:447-478
pubmed: 30200854
Science. 2004 Mar 5;303(5663):1526-9
pubmed: 14976262
Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70
pubmed: 27045557
Nat Rev Mol Cell Biol. 2020 Sep;21(9):501-521
pubmed: 32424334
Biomaterials. 2015 Oct;67:274-85
pubmed: 26231918
Curr Opin Pharmacol. 2018 Aug;41:104-113
pubmed: 29870915
Nat Protoc. 2020 Nov;15(11):3678-3698
pubmed: 33097923
Science. 2020 Feb 21;367(6480):
pubmed: 32079747
Nat Rev Microbiol. 2020 Feb;18(2):113-119
pubmed: 31695182
Science. 2013 May 10;340(6133):701-6
pubmed: 23661752
Science. 2002 May 17;296(5571):1319-21
pubmed: 12016316
Cancer Res. 2013 Mar 15;73(6):1709-20
pubmed: 23338611
Nature. 2001 Oct 18;413(6857):732-8
pubmed: 11607032
EBioMedicine. 2019 Mar;41:146-155
pubmed: 30852164
Nat Rev Immunol. 2019 Jan;19(1):31-44
pubmed: 30301972
Front Immunol. 2013 Jan 10;3:406
pubmed: 23335921
Nucleic Acids Res. 2017 Feb 28;45(4):2210-2220
pubmed: 28108656
Adv Drug Deliv Rev. 2022 Feb;181:114081
pubmed: 34915069
J Endotoxin Res. 2004;10(6):406-12
pubmed: 15588423
J Immunol. 2005 Feb 1;174(3):1259-68
pubmed: 15661881
Nat Rev Chem. 2020 Jan;4(1):22-37
pubmed: 32984545
Mol Ther Nucleic Acids. 2022 Jan 10;27:894-915
pubmed: 35141049
Trends Immunol. 2017 Mar;38(3):194-205
pubmed: 28073693
Cancer Res. 2003 Nov 1;63(21):7483-9
pubmed: 14612549
Adv Drug Deliv Rev. 2021 Sep;176:113835
pubmed: 34144087
Nano Lett. 2018 Jul 11;18(7):4309-4321
pubmed: 29894623
Nucleic Acids Res. 2000 Jan 1;28(1):375-6
pubmed: 10592279
Nature. 2003 Jul 17;424(6946):324-8
pubmed: 12819664
Methods Mol Biol. 2017;1632:269-283
pubmed: 28730446
Nat Rev Immunol. 2015 Sep 15;15(9):529-44
pubmed: 26292638
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
Immune Netw. 2018 Aug 13;18(4):e27
pubmed: 30181915
Small. 2011 Jun 20;7(12):1673-82
pubmed: 21538862
Mol Ther. 2011 Oct;19(10):1878-86
pubmed: 21829171
Molecules. 2019 Mar 20;24(6):
pubmed: 30897721
Front Mol Neurosci. 2020 Jan 10;12:314
pubmed: 31998072
Nanomedicine. 2021 Aug;36:102418
pubmed: 34171470
Curr Opin Chem Biol. 2019 Oct;52:72-78
pubmed: 31238268
J Control Release. 2016 Dec 28;244(Pt A):98-107
pubmed: 27847326
Cell. 2017 Jul 13;170(2):352-366.e13
pubmed: 28709002
Int Immunol. 2008 May;20(5):709-18
pubmed: 18397908
Gut. 2014 Dec;63(12):1960-1971
pubmed: 24561613
Nature. 2019 Mar;567(7747):262-266
pubmed: 30842662
Front Immunol. 2012 Feb 02;3:9
pubmed: 22566895
Adv Funct Mater. 2018 Nov 28;28(48):
pubmed: 31258458
Immunol Rev. 2021 Nov;304(1):154-168
pubmed: 34514601
Oncotarget. 2018 Jun 22;9(48):29007-29017
pubmed: 29989043
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
Cell. 2021 Sep 16;184(19):4981-4995.e14
pubmed: 34464586
Cell Mol Gastroenterol Hepatol. 2019;7(2):371-390
pubmed: 30704985
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282829
Science. 2006 Nov 10;314(5801):997-1001
pubmed: 17038589
Adv Drug Deliv Rev. 2021 Jun;173:427-438
pubmed: 33857556
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Nucleic Acids Res. 2014 Feb;42(3):2085-97
pubmed: 24194608
mBio. 2018 Jul 3;9(4):
pubmed: 29970461
Mol Ther Nucleic Acids. 2020 Sep 4;21:192-204
pubmed: 32585627
J Control Release. 2015 Sep 10;213:142-151
pubmed: 26151705
Mol Cancer Ther. 2021 Jun;20(6):961-974
pubmed: 33850005
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34607895
PLoS One. 2020 Oct 29;15(10):e0240403
pubmed: 33119613
Mol Cell Biol. 2015 May;35(10):1848-59
pubmed: 25776554
Nano Lett. 2022 Jul 27;22(14):5961-5972
pubmed: 35786891
Oncotarget. 2016 Apr 26;7(17):23182-96
pubmed: 26992239
Science. 2022 Aug 12;377(6607):eabm4096
pubmed: 35951700
Nanomedicine. 2020 Jan;23:102094
pubmed: 31669854
Int Rev Immunol. 2014 Nov-Dec;33(6):443-53
pubmed: 24911430
J Biol Chem. 2007 Mar 9;282(10):7668-78
pubmed: 17209042
J Exp Med. 2022 Jan 3;219(1):
pubmed: 34757384
Curr Biol. 2020 Oct 5;30(19):R1189-R1202
pubmed: 33022264
J Neuroinflammation. 2020 May 1;17(1):139
pubmed: 32357908
Cancer Res. 2018 Nov 1;78(21):6183-6195
pubmed: 30224377
Cell Death Differ. 2014 Dec;21(12):1825-37
pubmed: 25012502
Nat Nanotechnol. 2010 Sep;5(9):676-82
pubmed: 20802494
J Exp Med. 2009 Jul 6;206(7):1589-602
pubmed: 19564349
J Clin Invest. 2008 Jan;118(1):376-86
pubmed: 18060045
AIDS. 2019 Jul 1;33(8):1315-1325
pubmed: 30932955
ACS Nano. 2019 Nov 26;13(11):12301-12321
pubmed: 31664817
Mol Ther. 2017 May 3;25(5):1069-1075
pubmed: 28366767
Nat Med. 2008 Nov;14(11):1256-63
pubmed: 18978796
RNA. 2001 Apr;7(4):499-512
pubmed: 11345429
Nat Nanotechnol. 2013 Apr;8(4):296-304
pubmed: 23542902
Expert Rev Vaccines. 2015 Mar;14(3):447-59
pubmed: 25308798
Cell Rep. 2018 Dec 18;25(12):3371-3381.e5
pubmed: 30566863
Acc Chem Res. 2014 Jun 17;47(6):1731-41
pubmed: 24758371
Front Microbiol. 2011 Dec 19;2:248
pubmed: 22194732
Chembiochem. 2003 Oct 6;4(10):979-83
pubmed: 14523914
Adv Drug Deliv Rev. 2022 Jan;180:114079
pubmed: 34902516
Cell. 2009 Aug 7;138(3):576-91
pubmed: 19631370